BAY-593

• Description:

  BAY-593 is an orally active GGTase-I inhibitor. BAY-593 can block YAP1/TAZ signaling in animals and has antitumor activity[1].

• UNSPSC:

  12352005

• Target:

  GGTase; YAP

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease; Stem Cell/Wnt

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bay-593.html

• Purity:

  99.94

• Solubility:

  DMSO : 116.67 mg/mL (ultrasonic)

• Smiles:

  O=C(N1CCC2(CCNC[C@@]2([H])C3=CC=CC=C3OC)CC1)[C@@](OC)(C(F)(F)F)C4=CC=CC=C4

• Molecular Formula:

  C26H31F3N2O3

• Molecular Weight:

  476.53

• References & Citations:

  [1]Graham K, et al. Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell Chem Biol. 2024 Mar 19:S2451-9456 (24) 00087-4.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  GGTase I

• CAS Number:

  [2413020-56-9]